Literature DB >> 10902798

Serum prostate-specific antigen concentrations are not useful for monitoring the treatment of hirsutism with oral contraceptive pills.

H F Escobar-Morreale1, S Avila, J Sancho.   

Abstract

Prostate-specific antigen (PSA) is produced in several female tissues, under the regulation of steroid hormones. Serum PSA levels are increased in women with hirsutism, and they correlate with serum androgen levels. Therefore, as a marker of androgen excess, measurement of serum PSA may play a role in monitoring the treatment of hirsutism with contraceptive pills. Sixteen hirsute patients were included in the study. Clinical and biochemical variables, including serum PSA (using an ultrasensitive chemiluminescent immunoassay), total testosterone, sex hormone-binding globulin, androstenedione, dehydroepiandrosterone-sulfate, estradiol, and gonadotropin concentrations were recorded at baseline and after 3 and 6 cycles of treatment with a monophasic contraceptive pill containing ethynylestradiol and desogestrel. Twenty-seven healthy women served as controls for serum PSA level and for the serum androgen profile. Serum PSA levels were higher in hirsute patients, as compared with healthy women (mean +/- SEM: 0.014 +/- 0.003 vs. 0.006 +/- 0.001 microg/L, P < 0.02). Despite a marked decrease in serum androgens (total testosterone and androstenedione, calculated free testosterone and free androgen index; and dehydroepiandrosterone-sulfate) and in the hirsutism score, and a marked increase in sex hormone-binding globulin levels, serum PSA levels did not change and remained detectable in all the hirsute patients after 3 and 6 cycles of treatment with contraceptive pills. In conclusion, the increased serum PSA levels present in hirsute patients do not change during treatment with contraceptive pills and do not parallel the amelioration in hirsutism and the decrease in serum androgen concentrations that occur during this treatment. Thus, serum PSA measurements have no apparent role in the management of hirsute patients on oral contraceptive treatment, at least with the ultrasensitive assays currently available.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10902798     DOI: 10.1210/jcem.85.7.6664

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Serum prostate-specific antigen concentration is increased in acromegalic women.

Authors:  L Manetti; I Lupi; M Genovesi; L Morselli; L Grasso; C Nencetti; M Gasperi; F Bogazzi; L Bartalena; E Martino
Journal:  J Endocrinol Invest       Date:  2004 Jul-Aug       Impact factor: 4.256

2.  Serum PSA levels are not affected by the menstrual cycle or the menopause, but are increased in subjects with polycystic ovary syndrome.

Authors:  A Burelli; R Cionini; E Rinaldi; E Benelli; E Fiore; D Canale; W Bencivelli; C Nencetti; A Pinchera; E Pucci
Journal:  J Endocrinol Invest       Date:  2006-04       Impact factor: 4.256

3.  A Study on Omentin-1 and Prostate Specific Antigen in Women on Treatment for Polycystic Ovary Syndrome.

Authors:  Anbalagan Anithasri; Palghat Harihara Ananthanarayanan; P Veena
Journal:  Indian J Clin Biochem       Date:  2017-12-11

4.  Diagnostic value of prostatic specific antigen in hirsute women.

Authors:  S Güllü; R Emral; M Asik; M Cesur; V Tonyukuk
Journal:  J Endocrinol Invest       Date:  2003-12       Impact factor: 4.256

Review 5.  Prostatic-specific antigen (PSA) levels in patients with polycystic ovary syndrome (PCOS): a meta-analysis.

Authors:  Zeng-Hong Wu; Yun Tang; Xun Niu; Fei-Fei Pu; Xi-Yue Xiao; Wen Kong
Journal:  J Ovarian Res       Date:  2019-10-15       Impact factor: 4.234

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.